The autoantibody response appears to be directed against epitopes located within either the Cg2-Cg3 interdomain region (aa301-339) or the Cg4 domain of IgE.9
The low affinity receptor for IgE (FccRII), also known as CD23, is found on a variety of cells, including lymphocytes, eosinophils, neutrophils, platelets, and macrophages. The binding of IgE to these cells and the subsequent interaction of receptor bound IgE with allergen leads to cellular activation and release of mediators of chronic allergic inflammation. The IgG autoanti-IgE is detectable in the serum of individuals showing enhanced IgE production, namely those with allergic asthma,5 allergic rhinitis,' and parasitic infestations.7 Investigations of the subclass profile of IgG autoanti-IgE have revealed that most of the activity is found in IgGI and IgG4, with IgG4 showing a disproportionately high percentage of the activity. 8 The autoantibody response appears to be directed against epitopes located within either the Cg2-Cg3 interdomain region (aa301-339) or the Cg4 domain of IgE. 9 We have previously shown that autoanti-IgE of the IgGl subclass blocks the binding of IgE to the high affinity receptor (FccRI), found on mast cells, basophils, and eosinophils.'0 Given that IgE binds to both types ofreceptor through sites within its CO3 domain," it would be interesting to examine the effect of autoanti-IgE on IgE binding to CD23. The availability of a human lymphoblastoid B cell line expressing CD23 (RPMI 8866 cells) provides a direct system for studying such molecular interactions by flow cytometry. In this study we demonstrate the ability of IgG anti-IgE containing sera, obtained from atopic rhinitis patients, to block the binding of IgE to CD23. (fig 1) , thus ensuring optimal sensitivity of the assay.
Methods
Twenty rhinitis patients' sera (containing anti-IgE) and 15 Having established the validity of our experimental system, we tested 20 serum samples, taken from rhinitis patients with positive titres of IgG1 or IgG4 anti-IgE, or both, for their ability to block the binding of IgE-FITC to the B cells. This revealed significant inhibition (greater than 20%) in 15 out of 20 sera tested. The inhibitory effect was recoverable in the IgG fraction of three out of four serum samples tested. However, the inhibitory effect was not related to the titres of IgGI anti-IgE, IgG4 anti-IgE, or IgE, thus suggesting that it might be related to epitope specificity of the antiIgE.9 None of the 15 rheumatoid sera tested, containing anti-IgG but lacking anti-IgE, was able to cause more than 20% inhibition of IgE binding to the B cells.
Although the IgG anti-IgE containing patients' sera caused modest inhibition (up to 48%) of IgE binding to the B cells, we believe that the experimental conditions used in this study underestimate the IgE blocking effect of anti-IgE in vivo. For instance, the inhibtion values presented in this paper were obtained using relatively high concentrations of IgE, thereby making the ratio of IgE to anti-IgE much greater than that in the circulation. '6 The demonstration that human autoanti-IgE blocks the binding of IgE to CD23 in vitro is of pathological significance, since this action will render CD23 available for enzymatic cleavage. This will lead to upregulation of IgE synthesis through both sCD23 release3 and disruption of the negative IgE regulatory signal delivered by membrane CD23 to the B lymphocyte. 4 The net effect of such excessive IgE production is the perpetuation of an ongoing allergic inflammation. A positive correlation has been reported between circulating levels of IgE and anti-IgE,57 providing in vivo evidence in support of a positive IgE regulatory role for autoanti-IgE.
We have recently shown that IgG autoantiIgE blocks the binding ofIgE to its high affinity receptor (FccRI), found on mast cells, basophils, and eosinophils.'0 In this context, IgG anti-IgE appears to have an anti-allergic effect, which is in marked contrast to the pro-allergic effect reported here. However, we have previously argued that the existence of epitope specific subpopulations of autoanti-IgE is clearly suggestive of a multiple role in immunological events involving IgE.8 This work is supported by a grant from the Wellcome Trust (grant number 036661/Z/92/Z).
